Sign Out
Romosozumab is a humanized monoclonal antibody (IgG2) produced in a mammalian cell line (Chinese Hamster Ovary) by recombinant DNA technology that binds to and inhibits sclerostin. Romosozumab has an approximate molecular weight of 149 kDa.
Two 105 mg/1.17 mL single-use prefilled syringes are required to administer the recommended 210 mg dose of EVENITY [see Important Dosage and Administration Instructions under Dosage & Administration]. Each single-use prefilled syringe delivers 1.17 mL of solution containing 105 mg of romosozumab, acetate (3.8 mg), calcium (0.61 mg), polysorbate 20 (0.07 mg) and sucrose (70 mg) in Water for Injection, USP, and sodium hydroxide to a pH of 5.2.
Continue with Google